VRAX Stock Risk & Deep Value Analysis
Virax Biolabs Group Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VRAX Stock
We analyzed Virax Biolabs Group Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VRAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is VRAX Stock?
Overall Risk
Aggressive
Financial Risk
Extreme
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for VRAX?
- âš
Imminent delisting due to non-compliance or lack of equity
- âš
Chapter 11 or Chapter 7 filing
- âš
Complete erosion of remaining equity value
Unlock VRAX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Virax Biolabs Group Ltd (VRAX) Do?
Market Cap
$2.70M
Sector
Healthcare
Industry
Biotechnology
Employees
19
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Visit Virax Biolabs Group Ltd WebsiteIs VRAX Stock Undervalued?
Unlock the full AI analysis for VRAX
Get the complete DVR score, risk analysis, and more
Does VRAX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
There is no discernible moat. Any intellectual property or customer relationships would likely be liquidated or lost in the event of insolvency.
Moat Erosion Risks
- •Insolvency leading to complete loss of assets and operations
- •Lack of funding to maintain any competitive edge
- •Loss of key personnel and relationships
VRAX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive VRAX Stock Higher?
Near-Term (0-6 months)
- •Potential delisting from exchange
- •Bankruptcy/liquidation announcement
Medium-Term (6-18 months)
- •Unlikely to exist given current status
- •Restructuring if not already insolvent
Long-Term (18+ months)
- •None observable; company survival is primary concern
- •Extreme speculation on a phoenix-like rise (highly improbable)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VRAX?
- ✓
Any public announcements regarding bankruptcy or delisting (negative)
- ✓
Any unexpected, significant capital injection or acquisition offer (highly unlikely positive, but would be a material change)
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VRAX (Virax Biolabs Group Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
